Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxcyte Inc (NQ: PCVX )

88.39 +2.43 (+2.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,981,455
Open 85.78
Bid (Size) 81.05 (4)
Ask (Size) 89.60 (7)
Prev. Close 85.96
Today's Range 85.33 - 92.87
52wk Range 48.24 - 121.06
Shares Outstanding 93,706,790
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
Via The Motley Fool
Topics Stocks
Exposures US Equities
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
10 worst performing large-cap stocks last week: MPWR, SMCI, MRNA, LDOS, MNDY, PCVX, BAH, ABBV, CACI, XPEV. Check if they're in your portfolio. 
Via Benzinga

Performance

YTD
+40.44%
+40.44%
1 Month
-21.54%
-21.54%
3 Month
+13.12%
+13.12%
6 Month
+27.60%
+27.60%
1 Year
+80.39%
+80.39%

More News

Read More
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Peering Into Vaxcyte's Recent Short Interest
Via Benzinga
Peering Into Vaxcyte's Recent Short Interest
Via Benzinga
PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024
Via InvestorPlace
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
Recap: Vaxcyte Q4 Earnings
Via Benzinga
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
Via Benzinga
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
Via Investor's Business Daily
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Appoints John Furey to Board of Directors
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
Via Benzinga
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.